Kiera Fallon, Research Associate II at CRISPR Therapeutics

Kiera Fallon

Research Associate II at CRISPR Therapeutics | Boston, Massachusetts, United States

Profile last verified July 2026
Biotechnology Verified Profile Boston, Massachusetts, United States Boston University
Verified

Personal Email

***@gmail.com

Personal • High Confidence

Phone Number

(413) ***-*795

United States • Phone

Free account · No credit card · 5 profiles/month

Kiera Fallon Socials
Kiera Fallon Work Experience

Research Associate II at CRISPR Therapeutics in June 2024 - Present

Business Development Representative at Sannova Analytical in January 2024 - November 2024

Reseach Associate II at Beam Therapeutics in June 2022 - November 2023

See more See less

Research Associate at Olink Proteomics in June 2021 - May 2022

Research Assistant at University of Massachusetts Amherst in January 2021 - May 2021

Teaching Assistant at University of Massachusetts Amherst in January 2021 - May 2021

Patient Access at MelroseWakefield Healthcare in June 2018 - May 2021

Kiera Fallon Education

Boston University, Master of Business Administration - MBA, August 2026

University of Massachusetts Amherst, Bachelor of Science - BS, August 2026

Kiera Fallon Skills
Interpersonal Skills Data Analysis Laboratory Skills Software Polymerase Chain Reaction (PCR) Protein Expression Chromatography Purification Data Entry Gas Chromatography DNA Extraction Research Next Generation Sequencing Communication Teamwork Protein Crystallization Crystallization Biological Data Analysis Affinity Chromatography Hydrophobic Interaction Chromatography PCR Primer Design Protein Assays Protein Electrophoresis Reagents Distillation Site-directed Mutagenesis Bacterial Transformation Data Analytics Proteomics
About Kiera Fallon’s Current Company
CRISPR Therapeutics

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Discover more about CRISPR Therapeutics
Kiera Fallon’s Colleagues
Hannah Nierle

Hannah Nierle

Greater Boston

Clinical Trial Manager at CRISPR Therapeutics

Clinical Trial Manager at CRISPR Therapeutics
(August 2025 – Present)

Sammy Hankaoui

Sammy Hankaoui

Greater Boston

Cell Therapy at CRISPR Therapeutics || MBA Candidate at WPI

Cell Therapy at CRISPR Therapeutics
(July 2023 – Present)

Aj Silver

Aj Silver

Suffolk County, Massachusetts, United States

Senior Vice President Finance

Senior Vice President Finance at CRISPR Therapeutics
(January 2025 – Present)

Q

Qichen

Boston, Massachusetts, United States

Scientist at CRISPR Therapeutics

Scientist, CRISPR-X at CRISPR Therapeutics
(June 2024 – Present)

MD

Marylee Dequeant

Greater Boston

Executive Director, Head of In Vivo Research | Immuno-Oncology | Cell and Gene Therapy | CRISPR | LNP Delivery | CAR-T | CTA and IND Strategy | Cross-Functional Leadership | Regulatory Interactions | AAV | Liver | Eye |

Head of In Vivo Research, Executive Director, and Immuno-Oncology Lead at CRISPR Therapeutics
(July 2024 – Present)

Aamir Mir

Aamir Mir

Cambridge, Massachusetts, United States

Senior Director at CRISPR Therapeutics

Senior Director, CRISPR-X at CRISPR Therapeutics
(Jul 2025 – Present)

Search similar profiles
Frequently asked questions about Kiera Fallon

What is Kiera Fallon email address?

Email Kiera Fallon at [email protected] and [email protected]. This email is the most updated Kiera Fallon's email found in 2026.

How to contact Kiera Fallon?

To contact Kiera Fallon send an email to [email protected] or [email protected]. (updated on July 2026)

What company does Kiera Fallon work for?

Kiera Fallon works for CRISPR Therapeutics.

What is Kiera Fallon's role at CRISPR Therapeutics?

Kiera Fallon is Research Associate II

What industry does Kiera Fallon work in?

Kiera Fallon works in the Biotechnology industry.

Find anyone, anywhere
with ContactOut today

Making remote or global hires? Connecting
with key decision-makers? We can help.

  • 40 emails / month
  • 3 phone numbers / month
  • Works on standard LinkedIn only
  • Work emails, personal emails,
    mobile numbers
* 1 user per company limit

No credit card required

Try ContactOut for Free